81. Modulation of brown adipocyte activity by milk by‐products: Stimulation of brown adipogenesis by buttermilk. (December 2016) Authors: Asano, Hiroki; Kida, Ryosuke; Muto, Kengo; Nara, Takayuki Y.; Kato, Ken; Hashimoto, Osamu; Kawada, Teruo; Matsui, Tohru; Funaba, Masayuki Journal: Cell biochemistry and function Issue: Volume 34:Number 8(2016) Page Start: 647 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
82. Monitoring of cancer patients via next‐generation sequencing of patient‐derived circulating tumor cells and tumor DNA. Issue 8 (23rd July 2019) Authors: Onidani, Kaoru; Shoji, Hirokazu; Kakizaki, Takahiko; Yoshimoto, Seiichi; Okaya, Shinobu; Miura, Nami; Sekikawa, Shoichi; Furuta, Koh; Lim, Chwee Teck; Shibahara, Takahiko; Boku, Narikazu; Kato, Ken; Honda, Kazufumi Journal: Cancer science Issue: Volume 110:Issue 8(2019) Page Start: 2590 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
83. Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol. Issue 9 (1st September 2022) Authors: Osumi, Hiroki; Ishizuka, Naoki; Takashima, Atsuo; Kumekawa, Yosuke; Nakano, Daisuke; Shiozawa, Manabu; Denda, Tadamichi; Sawada, Ryoichi; Ouchi, Kota; Wakatsuki, Takeru; Narikazu, Boku; Kato, Ken; Yamaguchi, Kensei; Shinozaki, Eiji Journal: BMJ open Issue: Volume 12:Issue 9(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
84. Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study. Issue 3 (15th February 2018) Authors: Kato, Ken; Ura, Takashi; Koizumi, Wasaburo; Iwasa, Satoru; Katada, Chikatoshi; Azuma, Mizutomo; Ishikura, Satoshi; Nakao, Yoshinori; Onuma, Hiroshi; Muro, Kei Journal: Cancer science Issue: Volume 109:Issue 3(2018) Page Start: 785 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
85. Nivolumab for the treatment of esophageal cancer. (3rd June 2021) Authors: Mikuni, Hayato; Yamamoto, Shun; Kato, Ken Journal: Expert opinion on biological therapy Issue: Volume 21:Number 6(2021) Page Start: 697 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
86. Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma. Issue 2 (2020) Authors: Okada, Mao; Yamamoto, Shun; Kato, Ken Journal: Oncology & hematology review Issue: Volume 16:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
87. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10111 (2nd December 2017) Authors: Kang, Yoon-Koo; Boku, Narikazu; Satoh, Taroh; Ryu, Min-Hee; Chao, Yee; Kato, Ken; Chung, Hyun Cheol; Chen, Jen-Shi; Muro, Kei; Kang, Won Ki; Yeh, Kun-Huei; Yoshikawa, Takaki; Oh, Sang Cheul; Bai, Li-Yuan; Tamura, Takao; Lee, Keun-Wook; Hamamoto, Yasuo; Kim, Jong Gwang; Chin, Keisho; Oh, Do-Youn Journal: Lancet Issue: Volume 390:Issue 10111(2017) Page Start: 2461 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
88. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Issue 2 (February 2022) Authors: Kang, Yoon-Koo; Chen, Li-Tzong; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Chung, Hyun Cheol; Lee, Keun-Wook; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi; Chung, Ik-Joo; Yamaguchi, Kensei; Kato, Ken; Sym, Sun Jin; Kadowaki, Shigenori; Tsuji, Kunihiro; Chen, Jen-Shi; Bai, Li-Yuan; Oh, Sun... Journal: Lancet oncology Issue: Volume 23:Issue 2(2022) Page Start: 234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
89. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Issue 5 (May 2017) Authors: Kudo, Toshihiro; Hamamoto, Yasuo; Kato, Ken; Ura, Takashi; Kojima, Takashi; Tsushima, Takahiro; Hironaka, Shuichi; Hara, Hiroki; Satoh, Taroh; Iwasa, Satoru; Muro, Kei; Yasui, Hirofumi; Minashi, Keiko; Yamaguchi, Kensei; Ohtsu, Atsushi; Doki, Yuichiro; Kitagawa, Yuko Journal: Lancet oncology Issue: Volume 18:Issue 5(2017:May) Page Start: 631 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
90. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Issue 11 (November 2019) Authors: Kato, Ken; Cho, Byoung Chul; Takahashi, Masanobu; Okada, Morihito; Lin, Chen-Yuan; Chin, Keisho; Kadowaki, Shigenori; Ahn, Myung-Ju; Hamamoto, Yasuo; Doki, Yuichiro; Yen, Chueh-Chuan; Kubota, Yutaro; Kim, Sung-Bae; Hsu, Chih-Hung; Holtved, Eva; Xynos, Ioannis; Kodani, Mamoru; Kitagawa, Yuko Journal: Lancet oncology Issue: Volume 20:Issue 11(2019) Page Start: 1506 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗